Qlucore, listed on Nasdaq First North, is launching a new Qlucore Insights test (Research Use Only) specifically developed for bladder cancer samples. The software-based test delivers multiple ...

Qlucore, a leader in software development for precision cancer diagnostics, received a prestigious grant of 2.5 million Euros during 2024. The grant is divided into four installments. The aim of the ...

Qlucore Diagnostics approved and CE-marked Third quarter, 1 November 2024 - 31 January 2025Net sales amounted to SEK 3,217k (4,835k).Operating result (EBIT) amounted to SEK -5,091k (-2,999k).Net ...

Qlucore, a developer of bioinformatics software, is expanding into the area of precision medicine and precision diagnostics. Qlucore has created a software platform for precision medicine and ...

Within the field of bioinformatics, scientists and organizations struggle with multiple problems. Key problems are the large amount of data and that the people who understand biology (or chemistry or) ...

Qlucore AB Annual stock financials by MarketWatch. View the latest QCORE financial statements, income statements and financial ratios.

The software‑based test delivers multiple clinically relevant results from a single whole‑transcriptome sequencing run, including detection of samples with high levels of the important MECOM gene.

Qlucore, a provider of scientific software, has won €600,000 ($801,360) over three years from the European Commission's 7th Framework Program to develop algorithms for use in personalizing treatment ...

David Eklund and Mats Svensson join Qlucore’s team of software developers, and Sara Strandberg will work as a sales representative with a focus on the North American market. David Eklund and Mats ...

While childhood cancer is rare (adult malignancies after 20 years are 20-30 times more common in general) it remains a major cause of death by disease in children. 15,700 children are diagnosed with ...

Net sales amounted to SEK 1,675k (3,427k). Operating result (EBIT) amounted to SEK -7,620k (-5,413k). Net result for the period amounted to SEK -7,529k (-5,000k). Earnings per share before dilution ...